Investment app to go live after smashing crowdfund target

Posted by 

SETsquared Bristol

Following their successful crowdfund raise of more than £440,000, SETsquared Bristol member, Stratiphy, a London-based fintech startup, will soon be launching an investment app.  

The app will allow users to trade according to risk profile, industry preferences and sustainability criteria. It uses powerful analytics to perform backtesting in seconds and compare multiple strategy scenarios.   

Stratiphy was set up during the pandemic but managed to smash its crowdfunding target by 220%, raising funds from 700 investors in 53 countries. 

The company is partnered with Sustainalytics, the global leader in ESG research and data, and its team includes advisors from banking, finance and Artificial Intelligence. CEO Dan Gold, previously worked in option pricing and bond yield forecasting for a banking giant, and Growth Lead Nikki Hawkes has a background in economics and actuarial science, analysing and calculating risk. 

Nikki said: “We can’t wait for the full version of the product to be live. Personalised, sustainable investing is the future and we are here to make it easier.” 

For more information, visit www.stratiphy.io

Recent News, Blogs and Stories

Ferryx exhibiting at Investment Futures event 2024

The Science Isn’t the Selling Point: Lessons from Founders

She spent nearly a decade on the science. Identified something that worked when nothing else did. Tested it. Patented it. Then she waited and nobody called. That was one of...
Tech-xpo 2021

SETsquared Announces Move to Temple Quarter Enterprise Campus

Engine Shed will close in December this year, marking the end of 13 impactful years supporting Bristol’s innovation community. SETsquared Bristol will continue its work uninterrupted, relocating to the University...
Neuronostics

Neuronostics recognised as a game-changer in Healthtech

Bristol-based digital health company Neuronostics has been celebrated as Most Transformative Healthtech Company at the OBN Awards 2025. The team behind BioEP™, Neuronostics’ digital biomarker, is revolutionising epilepsy diagnosis by...

SUCCESS IS THE GOAL

Fast track your technology business